Amgen swoops in with $13.4B deal to pluck blockbuster Otezla from Celgene
Now that their Enbrel franchise appears to be secure from copycat interlopers, Amgen is going for a sure thing on the deal side to bolster its revenue projections.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 159,000+ biopharma pros reading Endpoints daily — and it's free.